Solara Active Pharma Sciences Completes Brazil Subsidiary Closure Process
Solara Active Pharma Sciences Limited has officially completed the closure of its wholly owned subsidiary in Brazil, with formal deregistration effective July 30, 2025. The non-operating entity contributed nil turnover and had nil net worth for FY ended March 31, 2025, representing a corporate housekeeping measure to streamline the subsidiary structure.
*this image is generated using AI for illustrative purposes only.
Solara Active Pharma Sciences Limited has formally completed the closure of its wholly owned subsidiary in Brazil, with the entity now officially deregistered with the Federal Revenue of Brazil, marking the end of its corporate presence in the South American market through this non-operating entity.
Official Deregistration Confirmation
Following the company's earlier intimation dated February 21, 2025, Solara Active Pharma Sciences LTDA, Brazil has been voluntarily deregistered with the Federal Revenue of Brazil, with the deregistration taking effect from July 30, 2025. The company has now provided formal confirmation of this closure through its latest regulatory disclosure.
| Parameter: | Details |
|---|---|
| Entity Name: | Solara Active Pharma Sciences LTDA, Brazil |
| Deregistration Date: | July 30, 2025 |
| Entity Status: | Non-operating, non-material wholly owned subsidiary |
| Reason for Closure: | No business activities/non-operational |
| Regulatory Authority: | Federal Revenue of Brazil |
Financial Impact Assessment
The Brazilian subsidiary had no financial contribution to the parent company's consolidated performance. According to the regulatory disclosure, the entity recorded zero business activity and maintained nil net worth.
| Financial Metric: | FY Ended March 31, 2025 |
|---|---|
| Turnover Contribution: | Nil |
| Net Worth: | Nil |
| Percentage of Consolidated Turnover: | 0% |
| Revenue Impact: | No impact on consolidated revenue |
Regulatory Compliance Framework
The closure has been disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in accordance with SEBI Master circular dated January 30, 2026. The company has confirmed that this was a straightforward voluntary closure rather than a sale or disposal transaction.
| Compliance Aspect: | Details |
|---|---|
| Regulation: | SEBI LODR Regulation 30 |
| Transaction Type: | Voluntary closure (not a sale/disposal) |
| Related Party Transaction: | Not Applicable |
| Sale Consideration: | Not Applicable |
| Scheme of Arrangement: | Not Applicable |
Corporate Housekeeping Measure
The closure represents a corporate streamlining initiative, allowing Solara Active Pharma Sciences to eliminate dormant entities from its subsidiary structure. Company Secretary and Compliance Officer Pooja Jaya Kumar has confirmed that all relevant information regarding this closure is available on the company's website at solaraco.in for stakeholder reference.
The formal completion of this closure process demonstrates the company's commitment to maintaining an efficient corporate structure by removing non-operational entities that serve no business purpose.
Historical Stock Returns for Solara Active Pharma Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.07% | -2.25% | -10.64% | -26.79% | +2.52% | -62.26% |
15
